Figure 10.

^CD7ΔCD7-CAR-T cells exert an antitumor capacity in T-ALL PDX model. A. General outline of the experiment. Primary T-ALL cells, previously propagated in B-NDG mice, were injected i.v. at 2×10⁶ cells/mouse in B-NDG mice. Half of the mice received i.v. injection of ^CD7ΔT cells, and the remaining half mice received ^CD7ΔCD7-CAR-T cells (1.2×10⁶), as well as IL-2 (50,000 IU/mouse) administered i.p. daily for 2 weeks. B. The survival of mice are analyzed by Mantel-Cox log-rank test and shown with Kaplan-Meier curves. **P<0.01. C. qPCR of CAR copies in peripheral blood at different time points after treatment. D. Spleens of treated (^CD7ΔCD7-CAR-T cells) and untreated (^CD7ΔT cells) mice. E. Representative images of CD7 IHC staining in different tissues after CAR-T-cell treatment. Compared with the group receiving ^CD7ΔT cells, infiltration of CD7 was significantly reduced in the group receiving CAR-T cells. Magnification: 400×. Scar bar: 20 μm. BM, bone marrow.